Help us improve guidance content on our website. Complete our short survey.
Scheduling (national classification system)
Scheduling is a national classification system that controls how medicines and chemicals are made available to the consumers in order to protect public health.
Medicines and chemicals are classified into Schedules according to the level of regulatory control over the availability of the medicine or chemical required to protect public health and safety. The Schedules are published in the Poisons Standard and are given legal effect through state and territory legislation.
For details go to Scheduling of medicines & poisons.
Key information
Scheduling
- Scheduling basics
- Advisory Committee on Chemicals Scheduling
- Advisory Committee on Medicines Scheduling
- Public notices about scheduling
- Update on Psilocybin and MDMA scheduling
- Implementation of decisions and actions following the review of chemical scheduling in relation to cosmetic and fragrance ingredients
- Scheduling legislation
- Scheduling news
Poisons Standard
- Introduction to the Poisons Standard
- The Poisons Standard (the SUSMP)
- AHMAC - Scheduling policy framework for medicines and chemicals
- Scheduling handbook: Guidance for amending the Poisons Standard
State and territory information
- State/Territory scheduling information
- Contacts for State/Territory medicines & poisons regulation units
- Australian State & Territory regulatory controls on Schedule 7 poisons
- Australian State & Territory variations from Part 4 of the Poisons Standard
Amending the Poisons Standard and consultation coversheets
- Scheduling handbook: Guidance for amending the Poisons Standard
- Application to amend the Poisons Standard
- Scheduling consultation coversheets
Reports
- Independent Expert Panel on MDMA and psilocybin
- Independent expert report on the risks of intentional self-poisoning with paracetamol
- An evaluation of the therapeutic value, benefits and risks of methylenedioxymethamphetamine (MDMA) and psilocybin for the treatment of mental, behavioural or developmental disorders
- Regulatory options for appropriate access and safety controls for alkyl nitrites - Public meeting questions and answers
Latest articles
- TGA makes final decision to reduce paracetamol pack sizesThe TGA has published a final decision to reduce the maximum size of packs for various paracetamol products.
- Removal of prescribing restrictions on ivermectinFrom 1 June 2023, prescribing of oral ivermectin for ‘off-label’ uses will no longer be limited to specialists such as dermatologists, gastroenterologists and infectious diseases specialists.
Understanding the changes to MDMA and psilocybin accessFrom 1 July 2023, authorised psychiatrists can prescribe psychedelic medicines to people with specific mental health conditions under strict controls.
Latest publications
- Notice of final decision to amend (or not amend) the current Poisons Standard - ACMS #40, ACCS #34, Joint ACMS-ACCS #32Public notice of final decision to amend (or not amend) the current Poisons Standard - ACMS #40, ACCS #34, Joint ACMS-ACCS #32
- Public submissions on interim decisions for scheduling matters referred to the ACMS #40, ACCS #35 and Joint ACMS-ACCS #32Public submissions on interim decisions for scheduling matters referred to the ACMS #40, ACCS #35 and Joint ACMS-ACCS #32 meetings held in November 2022
- Public submissions on scheduling matters referred to the ACMS #40, ACCS #35 and Joint ACMS-ACCS #32 held in November 2022 (including paracetamol)Public submissions on interim decisions for scheduling matters referred to ACMS, ACCS and Joint meetings held in November 2022